Rugo HS et al., 2017-02-14: Prospective cohort at five US centres: 66.3% of 101 evaluable cooled patients had 50% or less hair loss versus 0 of 16 controls. No patient in the cooling group received an anthracycline, so it says nothing about anthracycline regimens.
Hair loss of 50% or less (Dean score of 0-2) was seen in 67 of 101 patients (66.3%; 95% CI, 56.2%-75.4%) evaluable for alopecia in the scalp cooling group vs 0 of 16 patients (0%) in the control group (P < .001).
Abstract, Results
Rugo HS et al., 2017-02-14: Prospective cohort at five US centres: 66.3% of 101 evaluable cooled patients had 50% or less hair loss versus 0 of 16 controls. No patient in the cooling group received an anthracycline, so it says nothing about anthracycline regimens. Not randomised (106 cooling vs 16 controls, 14 matched on age and regimen), and the authors say so. Co-author E. Bagemann is affiliated with Dignitana AB, the device maker. Comparator: no scalp cooling. Trial NCT01831024. Authors report ICMJE disclosure forms with 'No other disclosures'. Study type: controlled study.
